ANDA 209011, held by Rising Pharmaceuticals. Montelukast Sodium.
As of Nov 21, 2026, ANDA 209011 (Montelukast Sodium), held by Rising Pharmaceuticals, was first approved by FDA on Apr 18, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 18, 2017 | Original application | Approved |
| Montelukast SodiumEQ 4MG BASE · tablet, chewable;oral | Montelukast Sodium | Rx |
| Montelukast SodiumEQ 5MG BASE · tablet, chewable;oral | Montelukast Sodium | Rx |
| May 17, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 17, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 18, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters